寶鷹股份(002047.SZ):航空城集團成為公司控股股東 實控人變更為珠海國資委
格隆匯1月21日丨寶鷹股份(002047.SZ)公佈,2020年1月21日,公司收到中國證券登記結算有限責任公司深圳分公司出具的《證券過户登記確認書》,古少明及寶賢投資協議轉讓給航空城集團的無限售流通股約2.95億股股份已於2020年1月20日完成了過户登記手續。
此次權益變動事項完成後,航空城集團直接持有公司股份約2.95億股(佔公司股本總額的22.00%),持有公司有表決權股份約3.56億股(佔公司股本總額的26.57%)。航空城集團成為公司單一擁有表決權比例最大的股東,為公司的控股股東,公司實際控制人變更為珠海市人民政府國有資產監督管理委員會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.